Tuberculosis of the Genitourinary System

Back

Practice Essentials

Genitourinary tuberculosis (GUTB) is defined as infection by Mycobacterium tuberculosis of the urinary tract or genitalia. The infection typically involves hematogenous spread of chronic latent pulmonary infection to the kidneys, epididymis, or fallopian tubes; prostate seeding has also been reported but is extremely rare. Other genitourinary organs are affected by local spread.[1]

Renal, ureteral, and bladder TB

In the kidneys, when multiple granuloma form at the site of metastatic foci, they are typically bilateral, cortical, and adjacent to the glomeruli, and they may remain inactive for decades. Although both kidneys are seeded, clinically significant disease, which is caused by capillary rupture and delivery of proliferating bacilli into the proximal tubules, usually develops in only one kidney. The medullary hypertonic environment impairs the phagocytic function.

Growing granuloma may erode into the calyceal system, spreading the bacilli to the renal pelvis, ureters, bladder, and other genitourinary organs. Depending on the status of the patient's defense mechanisms, fibrosis and strictures may develop with chronic abscess formation. Extensive lesions can result in nonfunctioning kidneys. Hypertension in persons with renal tuberculosis (TB) is twice as common as it is in the general population.

Ureteral TB is an extension of the disease from the kidneys, generally to the ureterovesical junction, and develops in about one half of all patients with renal TB. It only rarely affects the middle third of the ureter.[2] Ureteral TB often causes ureteral strictures and, sometimes, hydronephrosis. Occasionally, severe cases can cause stricture of virtually the entire ureter.

Bladder TB is secondary to renal TB and usually starts at the ureteral orifice. It initially manifests as superficial inflammation with bullous edema and granulation. Fibrosis of the ureteral orifice can lead to stricture formation with hydronephrosis or scarification (ie, golf-hole appearance) with vesicoureteral reflux. Severe cases involve the entire bladder wall, where deep layers of muscle are eventually replaced by fibrous tissue, thus producing a thick fibrous bladder. Tubercles are rare in the bladder; if present, they usually appear at the ureteral orifice. Malignancy should be considered with any isolated tubercles away from the ureteral orifices.

Epididymal and testicular TB

The higher frequency of isolated epididymal TB lesions in children favors the possibility of hematologic spread of infection , whereas adults seem to develop tuberculous epididymoorchitis caused by direct spread from the urinary tract.[3] The formation of a draining sinus is uncommon in developed countries, but epididymal induration and beading of the vas are common.

Involvement of the testis is usually due to direct extension. Infertility may result from bilateral vasal obstruction. Nodular beading of the vas is a characteristic physical finding, and orchitis and the resulting testicular swelling can be difficult to differentiate from other mass lesions of the testes.

Prostatic TB

Prostatic TB is also spread hematogenously, but involvement is rare; however, of those with affected, 85% also have renal TB. The affected prostate is nodular and not tender to palpation. Severe cases may cavitate and form a perineal sinus, although this development is rare. Decreased semen volume may indicate extensive prostatic disease or ejaculatory duct obstruction.[4]

Genital and urethral TB

Urethral TB is secondary to genital TB. Patients with genital and urethral TB present with a superficial tuberculous ulcer on the penis or in the female genital tract secondary to mycobacteria exposure during intercourse. The penile ulcer may cause cavernositis that extends to the urethra. This form of TB may involve the uterus and fallopian tubes, causing strictures. Consider malignancy if genital ulcers are present. Acute urethritis manifests as mycobacterial discharge and often results in chronic stricture formation.

Pathophysiology and Etiology

The most common pathogen associated with tuberculosis (TB) is Mycobacterium tuberculosis, a strictly aerobic nonmotile bacterium. The bacterium grows slowly, dividing only once every 24 hours, and is capable of surviving within immune cells after phagocytosis. Uncommonly implicated pathogens include M kansasii, M fortuitum, M bovis, M avium-intracellulare (MAI), M xenopi, M celatum.

M tuberculosis bacilli are inhaled through the lungs to the alveoli, where they are phagocytosed by polymorphonuclear leukocytes and macrophages. Although most bacilli are initially contained, some are carried to the region's lymph nodes. Eventually, the thoracic duct may deliver mycobacteria to the venous blood; this may result in seeding of different organs. In addition, multiple granuloma form at the site of metastatic foci.[5]  

Male genital TB is usually a manifestation of the usual pulmonary acquisition of TB. Venereal acquisition of male genital tuberculosis is unlikely, although cases of male-to-female transmission of genital TB have been reported. Human immunodeficiency virus (HIV) infection increases the risk for active TB and has been suggested to increase the risk for reactivation of dormant foci; epididymal TB most commonly develops in sexually active young men.

In very rare cases, TB epididymitis[6, 7, 8] and prostatic TB[9] have been reported following intravesical bacille Calmette-Guérin (BCG) therapy for superficial bladder tumors, presumably due to retrocanalicular descent of organisms from the prostatic urethra.

Generally, TB prostatitis results from hematogenous dissemination of M tuberculosis from the site of the primary infection. Thus, previous infection with TB is the most important risk factor. Historically, 10-12% of men with TB had pathologic evidence of prostatic involvement during autopsy. Theories of descending spread via infected urine have been abandoned, largely in light of animal studies demonstrating hematogenous spread and the scarcity of prostatic urethral TB in association with prostatic parenchymal TB.

Prolonged steroid use and immunosuppressive therapy may increase the risk of reactivation of dormant foci.

Epidemiology

GUTB, which accounts for 20–40% of extrapulmonary tuberculosis (EPTB) cases, is the second most common site in developing and third most common site in developed nations.[10]  GUTB affects the kidney in 74% of cases (haematogenous spread) followed by epididymis, testis, bladder, ureter and prostate gland.[11]   Isolated involvement of genital organs is reported in about 5–30% of the cases of GUTB, with higher rates in epidemic situations.[10]

Case reports of prostatic TB in immunocompetent men note patient age ranges of 26-85 years. Reported cases of prostatic TB in men with HIV infection document presentation in men aged 30-47 years. Kulchavenya and Khomyakov reported on a series of 58 Siberian men with prostatic TB whose mean age was 49 years.[12]

Prognosis

Worldwide, 10 million people per year contract tuberculosis (TB), of which 3 million die annually. The ultimate prognosis is determined by the degree of systemic illness. However, good outcomes can generally be achieved in young patients, individuals without comorbid conditions, those who comply with medications and follow-up care, and patients with a good social support system. Early detection of the disease and sensitivity to first-line medications are also associated with a good.

There is a poorer prognosis in older patients, individuals from low socioeconomic groups, and those with comorbid immunocompromising conditions. Late detection with complications is also associated with a poor outcome.

In cases of epididymal and testicular TB, scrotal surgery may be required, which could include removal of the epididymis and testicle.

Male factor infertility, which manifests as decreased ejaculate volume, oligospermia, azoospermia, and leukocytospermia, has been observed in association with TB prostatitis. A perineal urinary fistula may result from tubercular cavern formation within or behind the prostate. Reports note perineal swelling, pain, and discharge preceding the development of the urinary fistula. Prostatic TB abscess formation has been noted, particularly in men with acquired immunodeficiency syndrome (AIDS).

Most patients with prostatic TB can be cured with early treatment with a multiple-drug regimen. Mortality directly attributable to prostatic TB has not been reported in the recent literature; however, a case report by Lanjewar and Maheshwari described 2 patients with human immunodeficiency virus (HIV) infection who died of disseminated TB during hospitalization.[13] Unsuspected tuberculous prostatic abscesses were noted in both patients during the postmortem examination.

Complications of genitourinary tuberculosis (GUTB) include the following:

Complications of advanced TB epididymitis include epididymal abscess and fistula formation. Both complications are usually treated with scrotal surgery. Failure of the anti-TB regimen to achieve satisfactory local response is also treated surgically.

History and Physical Examination

Clinical manifestations of GUTB are non-specific, depending on the organs affected and the severity of their involvement, and can mimic several urologic and gynecologic diseases. Physicians must have a high degree of awareness to make the diagnosis. 

General presentation

Persons with GUTB rarely display the typical symptoms of TB. GUTB Symptoms are generally chronic, intermittent, and nonspecific, although asymptomatic patients are not uncommon.

GUTB often manifests as repeated urinary tract infections that do not respond to the usual antibiotics. The most common symptoms of GUTB, in descending order of frequency, include increased frequency of urination (during the day initially but at night later in the disease course), dysuria, frank pain, suprapubic pain, blood or pus in the urine, and fever. Urinary urgency is relatively uncommon unless the bladder is extensively involved. Patients with GUTB may also present with a painful testicular swelling, perianal sinus, or genital ulcer.

Unexplained infertility in both men and women is sometimes attributable to GUTB.[14] Physicians have also diagnosed endometrial TB while seeking the cause of congenital TB in the newborn.

Epididymal TB presentation

The formation of granulomas in the epididymis is responsible for the clinical manifestations of epididymal TB, as in other organ systems. The typical presentation in a patient with epididymal TB is painful unilateral enlargement of the scrotum. Malaise, fevers, and chills are also common in affected patients.

Voiding problems are usually absent when only the external genitalia are involved. However, associated renal, vesical, or prostatic TB may contribute to irritative voiding symptoms.

Epididymal TB can result in infertility.[3]

Prostatic TB presentation

The often-incidental finding of TB in chips from transurethral resection of the prostate (TURP) procedures suggests that many men may not have symptoms attributable to prostatic TB. Nonspecific symptoms, including irritative voiding, may be the only complaints. Of men with prostatic TB, 50% have dysuria and 40% have perineal pain.

Sterile urethral discharge and terminal hematuria may herald TB prostatitis. Perineal pain, swelling, and drainage can account for a less common but more overt presentation. In addition, patients may present with male factor infertility, a well-described complication of prostatic TB. Perineal urinary fistula has also been reported.

Renal TB, which is a common comorbidity of prostatic TB, may manifest as flank pain. Significant differential diagnostic overlap requires maintaining a high index of suspicion for prostatic TB, particularly in men with a history of exposure to or infection with TB.

The most dramatic presentations of prostatic TB may be those in men with acquired immunodeficiency syndrome (AIDS). At least 6 cases of TB prostatic abscesses have been reported in men with human immunodeficiency virus (HIV) infection. Unlike the more insidious presentations noted in immunocompetent men, these patients presented with fever, perineal pain, and urinary hesitancy; 2 of the patients also presented with mental status changes.

Physical findings

Although the hallmark of GUTB is sterile pyuria, up to 20% of patients develop a secondary coliform infection. Gross hematuria occurs in 10% of cases and is usually total and painless; microscopic hematuria is present in 50% of cases.

Tender testicular or epididymal swelling, beading of the spermatic cord, and epididymocutaneous sinus formations may develop. In the early phases, TB epididymitis is indistinguishable from bacterial epididymo-orchitis. The scrotal contents are enlarged and tender, with loss of definition between the epididymis and testicle.

Secondary TB involvement of the testicle can be observed in advanced cases. Prostatic examination may reveal induration or bogginess of the prostate if this organ is involved. The vas deferens may be enlarged and beaded. Occasionally, a draining sinus is based posteriorly upon the epididymis.

Most patients with prostatic TB in contemporary series have a prostate that may be hard, irregular, nodular, or granular. In patients with a prostatic TB abscess, a soft fluctuant mass has been noted. Tenderness varies with the acuity of the process. Prostatic TB should be suspected in patients who have a draining perineal fistula.

Diagnostic Considerations

The most common reasons for delayed diagnosis are absence of typical clinical features and the tendency of UGTB to be masked by another diseases, including urinary tract infections (UTIs) from other pathogens. UTIs should be ranked first in a differential diagnosis with UGTB. Presence of various pathogens in urine makes identification of Mycobacterium tuberculosis (Mtb) difficult and a patient with pyuria and bacteriuria often receives multiple courses of antibiotics instead of being investigated for UGTB. In one series, comorbid UTI was found in 65.1% of UGTB cases.[15]

Significant differential diagnostic overlap requires maintaining a high index of suspicion for prostatic TB, particularly in men with a history of exposure to or infection with TB.

Because TB epididymitis often goes unsuspected during management of refractory epididymo-orchitis in developed countries, the ultimate diagnosis of TB epididymitis is usually made when the pathologic specimen from epididymo-orchiectomy is examined.

Conditions that should be considered include bladder, testicular, renal, and urethral cancer; fungal and bacterial infections of the GU tract; pyonephrosis; scrotal or testicular trauma; postsurgical granulomatous prostatitis; post–bacille Calmette-Guérin (BCG); and granulomatous and bacterial prostatitis. Consider renal tuberculosis (TB) in any patient with a nondiscrete renal calcification. In addition, perform a full workup for malignancies if tubercles or ulcers are present away from ureteric orifices, if genital ulcers are present, or with suspicious renal lesions.

Differentials

Consider the following:

Laboratory Studies

In addition to the patient history, a combination of laboratory and imaging studies, as well as other diagnostic studies can pin down the diagnosis.

Complete blood cell (CBC) count, erythrocyte sedimentation rate (ESR), serum chemistry, and C-reactive protein (CRP) studies are helpful to assess the severity of disease, renal function, and response to treatment. The ESR is commonly elevated in patients with epididymal tuberculosis, and its normalization can be used to follow the course of therapy.

Human immunodeficiency virus (HIV) testing should be offered to all patients with TB.

PPD Skin Test

Intradermal injection of purified protein derivative of tuberculin (PPD) is an important component of the TB evaluation. An indurated area larger than 10 mm in diameter is considered a positive result, and an area greater than 15 mm in diameter may indicate active disease. However, a positive test result, in and of itself, is not confirmatory of the diagnosis of active TB. Tuberculin skin test results are positive in about 90% of patients, but this finding denotes only previous inhalation of mycobacteria rather than active disease. Furthermore, false-negative test results in the setting of malignancy, immunosuppression, liver disease, and nutritional deficiencies must be considered.

When prostatic involvement is suspected in patients without a previous diagnosis of TB, a PPD test is a standard means of documenting exposure. False-negative results are possible, particularly during the 4-6 weeks before hypersensitivity develops and in persons who are immunosuppressed owing to various sources.

Urine Studies

Serial early-morning urine cultures (at least 3) for acid-fast bacilli (AFB) are still considered the criterion standard for evidence of active tubercular disease, with a sensitivity of 65% and a specificity of 100%. Every effort should be made to process the samples immediately after collection. Sending cultures before starting anti-TB treatment and adjusting therapy according to sensitivity in case of resistance is always recommended. The following methods are available:

Standard microbiologic identification of prostatic involvement of M tuberculosis also relies on culture and AFB staining results of semen and urine.

Findings that demonstrate microscopic hematuria, albuminuria, or sterile pyuria should raise suspicion for genitourinary TB but do not definitively establish the diagnosis.

Semen Analysis and PSA

Although it is not a required test, semen analysis may be useful in the evaluation of male infertility associated with prostatic TB. Standard microbiologic identification of prostatic involvement of M tuberculosis also relies on culture and acid-fast bacilli staining results of semen and urine.

Prostate-specific antigen (PSA) levels are elevated in only one third of patients with prostatic TB. 

Nucleic acid amplification tests (NAATs)

Nucleic acid amplification tests (NAATs) can yield results in between 2 to 48 hours. NAATs are classified by their mechanism: polymerase chain reaction (PCR) tests, ligase chain reaction (LCR) tests and variants of PCR such as Xpert MTB/RIF. 

The Xpert MTB/RIF assay simultaneously detects Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) in less than 2 hours. Xpert MTB/RIF is the World Health Organization's recommended initial diagnostic test for all patients with sign and symptoms of TB.[16]  A systematic review and meta-analysis reported sensitivity ranging from 83% to 95% and specificity from 79% to 99%.[1]

PCR has been extensively studied and has been proven highly sensitive, specific, and rapid. In various studies, data show a sensitivity ranging from 87% to 100% (usually > 90%) and a specificity from 92% to 99.8% (usually > 95%). Compare this with cultures (37%), bladder biopsies (47%), and intravenous pyelography (IVP) examinations (88%).[17]

Along with an accurate clinical assessment, PCR results are available in about 6 hours. The following PCR tests are available with near-equivalent quality:

DNA probes provide species specification in a few hours.

Staining with auramine or rhodamine and examining via fluorescence microscopy can be used to detect low numbers of mycobacteria. Luciferase bioluminescence is used to diagnose tuberculosis and aid in susceptibility testing.

 

Imaging Studies

Radiography

Chest and spine radiographs may show old or active pulmonary tubercular (TB) lesions. However, in 50% of patients, chest radiographic findings are negative.

Kidney, ureter, and bladder (KUB) radiographs reveal calcifications in the kidney and ureter in approximately 50% of patients. Calcifications are intraluminal, as opposed to schistosomiasis cases, which produce intramural calcifications. Calcifications in the bladder are uncommon.

Plain abdominal radiography is useful to search for evidence of renal or ureteral tuberculosis (ie, renal or ureteral calcifications).[13]

CT Scanning and MRI

This imaging study is a useful adjunct to intravenous pyelography (IVP) and is helpful in late or advanced disease for assessing the extent of disease and the indirect functional status of the affected kidney compared with the normal opposite kidney. This study is very sensitive for detecting calcification and thickened walls of the ureter and bladder.[21]

Nonvisualization of the affected kidney via excretory urography indicates advanced disease.

On a contrast-enhanced computed tomography (CT) scans, prostatic tuberculosis (TB) may appear as hypodense lesions within the prostate. Additionally, focal calcifications may be identified.

Magnetic resonance imaging is sometimes useful to reveal radiographic changes in genitourinary tuberculosis and may reveal low signal-intensity lesions suggestive of abscess in prostatic tuberculosis. These studies may also be useful in delineating the extent of any renal disease.

Ultrasonography

Ultrasonography may reveal cystic or cavitary lesions, cortical scarring, hydronephrosis, and abscess in the kidneys; ultrasonography is also very sensitive in testicular tuberculosis (TB). In cases of female genital TB, an adnexal mass, thickened omentum or peritoneum, peritoneal tubercles, loculated or free fluid in the pelvic cavity, and adhesions are common ultrasonographic findings.

High-resolution transrectal ultrasonography (TRUS) has become a very useful noninvasive technique in the evaluation of the subfertile man who has severe oligospermia or azoospermia associated with a low-volume ejaculate.[22]  TRUS can reveal abnormalities in the seminal vesicles and ejaculatory duct and can help assess the status of the prostate. It may show dilatation or fibrosis of the epididymis, atrophy, thickening or calcification of the seminal vesicles, or prostatitis.

In persons with a soft or fluctuant prostate in whom an abscess is suspected, TRUS is particularly useful, as this modality allows demonstration and localization of the collection and can then guide transrectal aspiration and drainage of any fluid for culture and microscopic examination.

Although scrotal ultrasonography is helpful in assessing for complications of epididymal tuberculosis, such as fistula or abscess formation, the appearance of epididymal TB on ultrasonography is not distinct from that of bacterial epididymo-orchitis.

Intravenous pyelography (IVP) and voiding cystography

Intravenous pyelography (IVP) and voiding cystography are the standard diagnostic imaging studies for renal tuberculosis (TB) and have 88-95% sensitivity. These studies also help define the extent and severity of the disease.

The earliest radiographically detectable changes are cavitary lesions that progress to the papilla and invade the collecting system, causing calyceal disruption. Findings of infundibular stenosis and multiple ureteral strictures are highly suggestive of renal TB. Later findings may include cortical necrosis, calcifications, and coalesced cavitary lesions with scarring, stricture, sinus, or abscess formation. A small contracted bladder suggests extensive bladder TB.

An IVP or a computed tomography scan should also be obtained to determine the presence of concurrent renal and prostatic TB. Of patients with prostatic TB, 72% have pathologic evidence of renal TB during autopsy. Voiding cystography has also been used to confirm and delineate the extent of a vesicoperineal fistula associated with prostatic TB.

Retrograde pyelography is rarely indicated except in patients with renal failure in whom the kidneys cannot excrete contrast and to evaluate stricture in the upper urinary tract. It also helps for sampling urine from individual kidneys for microbiology.

Other imaging studies

Angiography is useful when focal lesions mimic a primary renal mass or when partial nephrectomy is planned. Angiography also shows obliterated interlobar arteries and avascular lesions.

Renal nuclear scan findings are nonspecific but can be used to assess kidney function and to monitor the effects of therapy.

Vasography in association with transrectal ultrasonography may demonstrate mechanical obstruction of the vas deferens.

Hysterosalpingography and image-intensifier endoscopy are sometimes useful to reveal radiographic changes in genitourinary tuberculosis.

 

 

 

Procedures

Consider biopsies of genital ulcers; tubercles in the bladder, especially if scattered away from the ureteric orifice (an uncommon feature of bladder tuberculosis [TB]); and any lesion with even a slight possibility of malignancy. The yield of biopsy for TB is about 45%.

Fine-needle aspiration (FNA) as a minimally invasive technique plays a prime role in the diagnosis of tubercular (TB) epididymitis and epididymo-orchitis.[23]  Acid-fast bacilli (AFB) may be detected on FNA smears in up to 60% of these patients. However, because of the risk of tumor spillage, FNA should be avoided if a neoplasm is suspected.[23, 24]

Histologic findings of TB epididymitis are similar to those of TB elsewhere in the body (granuloma formation, nonspecific inflammatory infiltrate). Additionally, mycobacteria are present. The granulomas appear with central Langerhans cells surrounded by lymphocytes, fibrocytes, and epithelioid cells, which later progress to central caseous formation and varying degrees of fibrosis and calcification. Similar histologic changes can be seen in the prostates of patients treated with intravesical bacillus Calmette-Guérin (BCG) for transitional cell carcinoma of the bladder.

Transrectal ultrasonography–guided needle biopsies have been used to obtain tissue for a definitive diagnosis of prostatic disease, to monitor response to therapy, and to ensure eradication of the prostatic TB.

Management Considerations

The primary aims of treatment are to preserve renal parenchyma and function, to make the patient noninfectious, and to manage comorbid conditions. Genitourinary tuberculosis (GUTB) responds better to a short course of treatment than pulmonary TB, because GUTB carries a lower mycobacterial load. Also, isoniazid (INH) and rifampin penetrate well into the cavitary lesions associated with GUTB. A high concentration of INH, rifampin, and pyrazinamide are maintained in the urine.

To prevent the emergence of resistant organisms, a multidrug regimen is the primary treatment. Because of the length of therapy and the adverse effects, maintaining patient compliance is difficult; therefore, directly observed therapy is often recommended.

Standard treatment of TB is rifampin, INH, pyrazinamide, and ethambutol for 2 months, then rifampin and INH for 4 more months unless resistance to either agent exists; if so, obtain a follow-up sensitivity report. Monitor culture and sensitivity reports and change the regimen if necessary. In general, a 4-month course of chemotherapy is recommended for GUTB (see Short-Course Therapy).

In patients who are positive for human immunodeficiency virus (HIV), continue treatment for a total of 9 months.

In malnourished patients, institute a high-nutrition diet.

Consultations

A urologist should provide constant follow-up care to prevent further irreversible parenchymal damage, and consultation with an infectious disease specialist is recommended for physicians who are not familiar with the treatment of TB. The expertise of a tuberculosis expert physician is of utmost importance to avoid acquired multidrug resistance and extremely high costs and difficult management.

Short-Course Therapy

A 4-month course generally is recommended for genitourinary tuberculosis. Examples of short-course therapy are as follows:

Special considerations apply to patients with impaired renal function. Rifampicin, isoniazid, pyrazinamide, ethionamide, and prothionamide may be given in normal doses, because these agents are either eliminated in the bile or broken down to metabolites that are not excreted by the kidney.

Ethambutol causes optic neuritis, which may be irreversible, and reduced doses should be given according to the glomerular filtration rate (GFR). Streptomycin and other aminoglycosides are ototoxic and nephrotoxic and should be avoided if possible in patients with impaired renal function.

Indications for prescribing steroids include severe bladder symptoms and tubular structure involvement (eg, ureter, fallopian tubes, spermatic cord).[25] High-dose prednisone (ie, at least 20 mg tid) for 4-6 weeks is recommended, because rifampicin reduces effectiveness and bioavailability of prednisone by 66%.

Management of Epididymal TB

The typical presentation of acute tuberculous (TB) epididymitis usually prompts antibiotic therapy for presumed acute bacterial epididymo-orchitis. A more insidious onset of symptoms, although not suggestive of acute bacterial epididymo-orchitis, often prompts the same therapy, because TB is usually not considered by the treating physician.

If no improvement occurs after 2-3 weeks of therapy for bacterial epididymo-orchitis, scrotal ultrasonography is useful to assess for complications of inadequately treated bacterial epididymo-orchitis. Ultrasonography also assists in the diagnosis of other elements in the differential diagnoses, including hydrocele, spermatocele, scrotal trauma, testicular malignancy, and neoplasms of the epididymis (see Ultrasonography).

If no such findings are noted, TB epididymitis or a resistant bacterial infection should be considered. Obtaining the purified protein derivative of tuberculin (PPD) skin test, serial first morning urine cultures for acid-fast bacilli (AFB), chest radiography, and abdominal radiography would be reasonable at this point. Additionally, a higher index of suspicion for epididymal TB is appropriate in men with HIV infection because of its increased incidence in this setting.

Chemotherapy may be instituted upon strong clinical suspicion of TB. Alternatively, fine-needle aspiration (FNA) of the epididymis can be performed to obtain material for smear examination (see Fine-Needle Aspiration). However, avoid this procedure if malignancy is suspected as seeding of the neoplasm may occur.

Management of TB Prostatitis

Once the diagnosis of tuberculous (TB) prostatitis is confirmed, the treatment is similar to that of other TB infections. This condition must be viewed as a systemic disease, and the treatment is primarily medical. Hospitalization is usually unnecessary but may be required to treat noncompliant patients. Patients should be isolated in a negative-pressure room, if available. In addition, the local health department should be notified to aid in identifying patient contacts. Drug susceptibility testing should be performed on the isolates obtained from the prostate.

Surgical Management

Although chemotherapy is the mainstay of treatment, surgical intervention, either as ablation or reconstruction, is often required during the course of genitourinary tuberculosis (GUTB). Generally, at least 4-6 weeks of chemotherapy with appropriate agents is first tried if immediate surgery is not necessary. 

Because diagnosis is often delayed and the narrow lumen of the ureteral tract is anatomically vulnerable to obstruction, a majority of patients present with urinary tract complications, such as a non-functioning hydronephrotic kidney, ureteral stricture, and a shrunk bladder.  Surgery is reportedly required in more than 50% of urinary tuberculosis patients.

Indications for surgical intervention

Indications for surgery include hydronephrosis, progressive renal insufficiency secondary to obstruction, nonfunctioning or poorly functioning kidneys, stricture of the fallopian tube or vas deferens that is causing infertility, persistent pain, possible neoplasm, recurrence of endometrial TB, and severe, persistent, or recurrent uterine bleeding.

During the course of treatment for epididymal TB, if the lesion loses its tenderness while maintaining nodularity, consider a testicular malignancy, in which case operative exploration is indicated. Additionally, because TB epididymitis often goes unsuspected in the management of refractory epididymo-orchitis in developed countries, the ultimate diagnosis of TB epididymitis is usually made when the pathologic specimen from epididymo-orchiectomy is examined. Alternative techniques, such as epididymectomy or fine-needle aspiration of the epididymis, can be offered if TB is suspected preoperatively.

In prostatic TB, some urologists advocate resection of the prostate, although only medical therapy is usually needed. In patients with obstructive symptomatology, resecting the prostate is reasonable. In addition, in resistant TB, prostate resection can theoretically lessen the infected tissue burden. Surgical treatment should be undertaken only once anti-TB therapy has been initiated to reduce the risk of exposure to the surgical team.

In persons infected with human immunodeficiency virus (HIV), prostatic TB can present as an abscess. Surgical drainage of an abscess collection is required. Wolf[26] and Moreno et al[27] described transrectal ultrasonography (TRUS)-guided needle drainage, and Trauzzi et al successfully treated one such patient with transurethral unroofing of the collection.[28] The surgeon should obtain intraoperative samples of any abscess fluid for acid-fast bacilli (AFB) staining, culture, and polymerase chain reaction (PCR), if available.

Ablative and reconstructive surgery

Ablative surgery is generally associated with partial or total nephrectomy, epididymectomy, salpingectomy, as well as other procedures.

Reconstructive surgery is considered for ureteric or urethral dilatation, stent placement, replacement or reimplantation, resection, urinary diversion, and augmentation cystoplasty.

Long-Term Monitoring

If the patient is not complying with therapy, use direct observation therapy 2-3 times a week.

Patients treated for epididymal TB should be monitored for resolution of symptoms and swelling of induration, which should begin within a few weeks. The urine generally clears of infectious organisms within 2 weeks.

In cases of prostatic TB, periodically check semen cultures to monitor treatment, and, if results are positive after 3 months, bacterial resistance to the current drug regimen or patient noncompliance should be strongly suspected. Histologic follow-up via repeat transrectal ultrasound-guided prostate biopsies has been recommended to ensure the efficacy of treatment.

Prevention

Patient education and monitoring are crucial to eradicating tubercular disease. Crucial education issues include long-term compliance, preventive measures, and early detection in other persons. In addition, patients should be advised to use condoms during intercourse. Sexual transmission of tuberculosis (TB) via infected semen has been reported to result in a vaginal TB ulcer. GUTB can be sexually transmitted until treatment clears mycobacteria from semen, urine, or other genital secretions. Mycobacteria usually clear approximately 4 weeks after appropriate medications are started. Inform patients that genitourinary tuberculosis (GUTB) may cause sterility in females, and consider genital TB in a male sex partner if the female has persistent, swollen, painful inguinal lymph nodes and no obvious source of infection.

Maintain a high degree of clinical awareness for genitourinary tuberculosis (GUTB). Screen emigrants from endemic areas as well as their sex partners and family members. Condom use is encouraged to prevent possible transmission to sexual partners. If an emigrant from a TB-endemic area has intermittent recurrent urinary tract infections after several courses of antibiotics, obtain a purified protein derivative (PPD) skin test and at least 3 serial early-morning urine samples to test for acid-fast bacilli to evaluate for GUTB.

Researchers now question the use of Bacille Calmette-Guérin (BCG) vaccine, even in developing countries, because TB is diagnosed in vaccinated persons. Additionally, the BCG vaccine is not cost-effective in developing countries.

Before starting medications, investigate regional drug-resistance data. The chemoprophylaxis protocol for unconfirmed clinical disease is isoniazid (INH) for 6 months (9 mo in patients who are positive for human immunodeficiency virus [HIV]), INH and rifampin for 3 months, or rifampin and pyrazinamide for 2 months.

 

Author

Klaus-Dieter Lessnau, MD, FCCP, Former Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory, Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Disclosure: Nothing to disclose.

Coauthor(s)

Andrew A Wagner, MD, Assistant Professor of Surgery and Urology at Harvard Medical School

Disclosure: Nothing to disclose.

Jason R Bylund, MD, Assistant Professor of Surgery, Division of Urology, University of Kentucky College of Medicine

Disclosure: Nothing to disclose.

Levi A Deters, MD, Attending Physician, Spokane Urology

Disclosure: Nothing to disclose.

Marcus Friedrich, MD, MBA, FACP, Medical Director Office of Quality and Patient Safety, New York State Department of Health; Assistant Professor, Hofstra North Shore-LIJ School of Medicine at Hofstra University

Disclosure: Nothing to disclose.

Mohamed S Soliman, MD, Consulting Staff, Integral Healthcare of Cheraw

Disclosure: Nothing to disclose.

Vernon M Pais, Jr, MD, Associate Professor, Department of Surgery, Section of Urology, Dartmouth Medical School

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Richard A Santucci, MD, FACS, Specialist-in-Chief, Department of Urology, Detroit Medical Center; Chief of Urology, Detroit Receiving Hospital; Director, The Center for Urologic Reconstruction; Clinical Professor of Urology, Michigan State University College of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Edward David Kim, MD, FACS, Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Endo.

Additional Contributors

Allen Donald Seftel, MD, Professor of Urology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School; Head, Division of Urology, Director, Urology Residency Training Program, Cooper University Hospital

Disclosure: Received consulting fee from lilly for consulting; Received consulting fee from abbott for consulting; Received consulting fee from auxilium for consulting; Received consulting fee from actient for consulting; Received honoraria from journal of urology for board membership; Received consulting fee from endo for consulting.

J Stuart Wolf, Jr, MD, FACS, David A Bloom Professor of Urology, Associate Chair for Urologic Surgical Services, Director, Division of Endourology and Stone Disease, Department of Urology, University of Michigan Medical School

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Shlomo Raz, MD, to the development and writing of a source article.

References

  1. Altez-Fernandez C, Ortiz V, Mirzazadeh M, Zegarra L, Seas C, Ugarte-Gil C. Diagnostic accuracy of nucleic acid amplification tests (NAATs) in urine for genitourinary tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2017 Jun 5. 17 (1):390. [View Abstract]
  2. Tian X, Wang M, Niu Y, Zhang J, Song L, Xing N. Retroperitoneal Laparoscopic Nephroureterectomy for Tuberculous Nonfunctioning Kidneys: a single-center experience. Int Braz J Urol. 2015 Mar-Apr. 41 (2):296-303. [View Abstract]
  3. Madeb R, Marshall J, Nativ O, Erturk E. Epididymal tuberculosis: case report and review of the literature. Urology. 2005 Apr. 65(4):798. [View Abstract]
  4. Paick J, Kim SH, Kim SW. Ejaculatory duct obstruction in infertile men. BJU Int. 2000 Apr. 85(6):720-4. [View Abstract]
  5. Kulchavenya E. Urogenital tuberculosis: definition and classification. Ther Adv Infect Dis. 2014 Oct. 2 (5-6):117-22. [View Abstract]
  6. Briceño-García EM, Gómez-Pardal A, Alvarez-Bustos G, Artero-Muñoz I, Molinero MM, Seara-Valero R, et al. Tuberculous orchiepididymitis after BCG therapy for bladder cancer. J Ultrasound Med. 2007 Jul. 26(7):977-9. [View Abstract]
  7. Salvador R, Vilana R, Bargalló X, Araque X, Nicolau C. Tuberculous epididymo-orchitis after intravesical BCG therapy for superficial bladder carcinoma: sonographic findings. J Ultrasound Med. 2007 May. 26(5):671-4. [View Abstract]
  8. Falkensammer C, Gozzi C, Hager M, Maier H, Bartsch G, Höltl L, et al. Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma. Urology. 2005 Jan. 65(1):175. [View Abstract]
  9. Aust TR, Massey JA. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy. Int J Urol. 2005 Oct. 12(10):920-1. [View Abstract]
  10. Yadav S, Singh P, Hemal A, Kumar R. Genital tuberculosis: current status of diagnosis and management. Transl Androl Urol. 2017 Apr. 6 (2):222-233. [View Abstract]
  11. Manso MC, Rodeia SC, Rodrigues S, Domingos R. Synchronous presentation of two rare forms of extrapulmonary tuberculosis. BMJ Case Rep. 2016 Apr 18. 2016:10.1136/bcr-2015-212917. [View Abstract]
  12. Kulchavenya E, Khomyakov V. Male genital tuberculosis in Siberians. World J Urol. 2006 Feb. 24(1):74-8. [View Abstract]
  13. Lanjewar DN, Maheshwari MB. Prostatic tuberculosis and AIDS. Natl Med J India. 1994 Jul-Aug. 7(4):166-7. [View Abstract]
  14. Lübbe J, Ruef C, Spirig W, Dubs M, Sigg C. Infertility as the first symptom of male genitourinary tuberculosis. Urol Int. 1996. 56(3):204-6. [View Abstract]
  15. Kulchavenya E, Cherednichenko A. Urogenital tuberculosis, the cause of ineffective antibacterial therapy for urinary tract infections. Ther Adv Urol. 2018 Mar. 10 (3):95-101. [View Abstract]
  16. [Guideline] World Health Organization. Using the Xpert MTB/RIF assay to detect pulmonary and extrapulmonary tuberculosis and rifampicin resistance in adults and children : expert group meeting report : 2013. WHO.int. Available at http://www.who.int/tb/publications/xpert-mtb-rif-assay-diagnosis-policy-update/en/. 2013; Accessed: May 4, 2018.
  17. Hemal AK, Gupta NP, Rajeev TP, Kumar R, Dar L, Seth P. Polymerase chain reaction in clinically suspected genitourinary tuberculosis: comparison with intravenous urography, bladder biopsy, and urine acid fast bacilli culture. Urology. 2000 Oct 1. 56(4):570-4. [View Abstract]
  18. D'Amato RF, Hochstein LH, Colaninno PM, Scardamaglia M, Kim K, Mastellone AJ, et al. Application of the Roche Amplicor Mycobacterium tuberculosis (PCR) test to specimens other than respiratory secretions. Diagn Microbiol Infect Dis. 1996 Jan. 24(1):15-7. [View Abstract]
  19. Hernandez A, Bergmann JS, Woods GL. AMPLICOR MTB polymerase chain reaction test for identification of Mycobacterium tuberculosis in positive Difco ESP II broth cultures. Diagn Microbiol Infect Dis. 1997 Jan-Feb. 27(1-2):17-20. [View Abstract]
  20. Shah S, Miller A, Mastellone A, Kim K, Colaninno P, Hochstein L, et al. Rapid diagnosis of tuberculosis in various biopsy and body fluid specimens by the AMPLICOR Mycobacterium tuberculosis polymerase chain reaction test. Chest. 1998 May. 113(5):1190-4. [View Abstract]
  21. Masuda H, Kamada K. IMAGES IN CLINICAL MEDICINE. Urinary Tract Tuberculosis. N Engl J Med. 2016 Sep 15. 375 (11):1068. [View Abstract]
  22. Li MK, Tan HH. Transrectal ultrasound in male infertility. Ann Acad Med Singapore. 1995 Jul. 24(4):566-8. [View Abstract]
  23. Sah SP, Bhadani PP, Regmi R, Tewari A, Raj GA. Fine needle aspiration cytology of tubercular epididymitis and epididymo-orchitis. Acta Cytol. 2006 May-Jun. 50(3):243-9. [View Abstract]
  24. Garbyal RS, Gupta P, Kumar S. Diagnosis of isolated tuberculous orchitis by fine-needle aspiration cytology. Diagn Cytopathol. 2006 Oct. 34(10):698-700. [View Abstract]
  25. Matsui K, Furumoto A, Ohba K, Mochizuki K, Tanaka T, Takaki M, et al. Use of Corticosteroids for Urinary Tuberculosis Patients at Risk of Developing Ureteral Obstruction. Intern Med. 2016. 55 (23):3539-3542. [View Abstract]
  26. Wolf LE. Tuberculous abscess of the prostate in AIDS. Ann Intern Med. 1996 Jul 15. 125(2):156. [View Abstract]
  27. Moreno S, Pacho E, López-Herce JA, Rodríguez-Créixems M, Martín-Scapa C, Bouza E. Mycobacterium tuberculosis visceral abscesses in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988 Sep 1. 109(5):437. [View Abstract]
  28. Trauzzi SJ, Kay CJ, Kaufman DG, Lowe FC. Management of prostatic abscess in patients with human immunodeficiency syndrome. Urology. 1994 May. 43(5):629-33. [View Abstract]

Genitourinary tuberculosis. Graph reporting cases of tuberculosis by disease form.